ESMO in Focus Webinar Asia - Gastrointestinal Cancers 2024

Description

This ESMO in Focus Webinar presented selected highlights of the ESMO Congress 2024.

This webinar focused on the practice-changing studies and new science presented on Gastrointestinal Cancers, and aimed to address how these new developments should be integrated into clinical practice in Asia.

The programme provided an expert overview and discussion of the latest developments in the management of patients with Gastrointestinal Cancers. Important abstracts, including late breaking, were put into perspective in relation to clinical practice in Asia. Finally, the experts addressed issues of particular interest to participants in a Q&A session.

References

509O: Total Neoadjuvant Treatment (TNT) with Non-Operative Management (NOM) for Proficient Mismatch Repair Locally Advanced Rectal Cancer (pMMR LARC): First Results of NO-CUT Trial

LBA2: POD1UM-303: Phase 3 Study of Retifanlimab With Carboplatin-Paclitaxel (C-P) in Patients With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal (SCAC) Not Previously Treated With Systemic Chemotherapy 

502O: Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: preliminary results of FFCD 1703 POCHI trial

LBA24: Neoadjuvant immunotherapy in locally advanced MMR-deficient (dMMR) colon cancer: 3-year disease -free survival from the NICHE-2 study 

950P: Outcomes by baseline tumour burden in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unresectable hepatocellular carcinoma (uHCC)

LBA3: Transarterial chemoembolization (TACE) with or without lenvatinib (len) plus pembrolizumab (pembro) for unresectable non-metastatic hepatocellular carcinoma (HCC): phase 3 LEAP-012 study

947MO: Five-year overall survival (OS) and OS by tumour response measures from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)

1401O: Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03)